

Cresemba - (372 mg/vial ; For Injection)

| | | | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | Isavuconazonium Sulfate | Innovator | Astellas |
| Dosage | 372 mg/vial ; For Injection | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | CRESEMBA ® is an azole antifungal indicated for use in the treatment of: • Invasive aspergillosis. • Invasive mucormycosis. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Cresemba - (186 mg ; Capsule)

| | | | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | Isavuconazonium Sulfate | Innovator | Astellas |
| Dosage | 186 mg ; Capsule | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | CRESEMBA ® is an azole antifungal indicated for use in the treatment of: • Invasive aspergillosis. • Invasive mucormycosis. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Cresemba - (74.5 mg ; Capsule)

| | | | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | Isavuconazonium Sulfate | Innovator | Astellas |
| Dosage | 74.5 mg ; Capsule | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | None | Generic Launches | None |
| Indication | CRESEMBA ® is an azole antifungal indicated for use in the treatment of: • Invasive aspergillosis. • Invasive mucormycosis. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.